Compare · JUPW vs NVO
JUPW vs NVO
Side-by-side comparison of Jupiter Wellness Inc. (JUPW) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JUPW and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 8792.9x JUPW ($21.3M).
- NVO has hit the wire 11 times in the past 4 weeks while JUPW has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for JUPW).
- Company
- Jupiter Wellness Inc.
- Novo Nordisk A/S
- Price
- $1.52+12.96%
- $42.01-2.10%
- Market cap
- $21.3M
- $187.53B
- 1M return
- -
- -5.38%
- 1Y return
- -
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 25
Jupiter Wellness Inc.
Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for use in the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CaniSun, a CBD-infused sunscreen; and CaniSkin, a CBD-infused skin care lotion. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest JUPW
- Jupiter Wellness Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Jupiter Wellness Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form EFFECT filed by Jupiter Wellness Inc.
- SEC Form POS AM filed by Jupiter Wellness Inc.
- Jupiter Wellness Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events (Amendment)
- SEC Form POS AM filed by Jupiter Wellness Inc.
- Jupiter Wellness Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form POS AM filed by Jupiter Wellness Inc.
- Jupiter Wellness Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Jupiter Wellness Inc. filed SEC Form 8-K: Regulation FD Disclosure
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates